Molecular property prediction is central to computational drug discovery, where graph neural networks learn to weight neighboring atomic environments during message passing. Yet it remains unclear how variational quantum circuits alter learned attention behavior in molecular graphs. We introduce an edge-aware variational quantum attention mechanism for molecular graph learning, in which the receiving atom, neighboring atom, and connecting bond jointly determine the quantum attention state. Across five molecular property and bioactivity prediction tasks, QGAT achieves competitive performance relative to GATv2, with a consistent improvement on BBBP across all six evaluated circuit ansatzes. We further compare how the quantum and classical attention scores weight molecular structure beyond accuracy. In the Verubecestat BACE1 inhibitor series, QGAT achieves a higher Spearman correlation than GATv2 and assigns positive attributions to several structural changes consistent with reported structure-activity relationships (SARs). This case study shows that the two attention mechanisms can exhibit different prediction and attribution behavior across structurally related BACE1 analogues, while broader validation is required to determine how consistently these differences generalize across chemical series and targets. Circuit ablations further show that performance depends on the circuit design. Together, these results show that variational quantum attention can serve as a viable alternative molecular attention parameterization while inducing circuit- and chemistry-dependent behavior distinct from a matched classical scorer.
Molecular property prediction is central to computational drug discovery, where graph neural networks learn to weight neighboring atomic environments during message passing. Yet it remains unclear how variational quantum circuits alter learned attention behavior in molecular graphs. We introduce an edge-aware variational quantum attention mechanism for molecular graph learning, in which the receiving atom, neighboring atom, and connecting bond jointly determine the quantum attention state. Across five molecular property and bioactivity prediction tasks, QGAT achieves competitive performance relative to GATv2, with a consistent improvement on BBBP across all six evaluated circuit ansatzes. We further compare how the quantum and classical attention scores weight molecular structure beyond accuracy. In the Verubecestat BACE1 inhibitor series, QGAT achieves a higher Spearman correlation than GATv2 and assigns positive attributions to several structural changes consistent with reported structure-activity relationships (SARs). This case study shows that the two attention mechanisms can exhibit different prediction and attribution behavior across structurally related BACE1 analogues, while broader validation is required to determine how consistently these differences generalize across chemical series and targets. Circuit ablations further show that performance depends on the circuit design. Together, these results show that variational quantum attention can serve as a viable alternative molecular attention parameterization while inducing circuit- and chemistry-dependent behavior distinct from a matched classical scorer.
We introduce Quantum Graph Attention Networks (QGATs) as trainable quantum encoders for inductive learning on graphs, extending the Quantum Graph Neural Networks (QGNN) framework. QGATs leverage parameterized quantum circuits to encode node features and neighborhood structures, with quantum attention mechanisms modulating the contribution of each neighbor via dynamically learned unitaries. This allows for expressive, locality-aware quantum representations that can generalize across unseen graph instances. We evaluate our approach on the QM9 dataset, targeting the prediction of various chemical properties. Our experiments compare classical and quantum graph neural networks-with and without attention layers-demonstrating that attention consistently improves performance in both paradigms. Notably, we observe that quantum attention yields increasing benefits as graph size grows, with QGATs significantly outperforming their non-attentive quantum counterparts on larger molecular graphs. Furthermore, for smaller graphs, QGATs achieve predictive accuracy comparable to classical GAT models, highlighting their viability as expressive quantum encoders. These results show the potential of quantum attention mechanisms to enhance the inductive capacity of QGNN in chemistry and beyond.
Graph Neural Networks (GNNs) are now one of the key tools to model relational and non-Euclidean data in multiagent systems, infrastructure networks and even molecular modeling applications. Nevertheless, in very dense or noisy graph topologies, classical message-passing architectures may experience scalability and representational degeneration, especially due to over-smoothing and insufficient higher-order dependency information. The recent developments in quantum machine learning indicate that hybrid quantum-classical models can also provide an alternative feature representation by projecting relational data to parameterized quantum circuits. This article presents a Quantum-Enhanced Graph Neural Network (QGNN) architecture that extends variational quantum circuits with graph learning pipelines, based on classical learning. Parameters are represented as parameterized qubits, and relational dependencies are represented as structured entanglement mappings. We benchmark the regimes where quantum-enhanced relational encoding proves to be more robust and stable through the swarm coordination, molecular property prediction, and financial transaction network. We also elaborate on the issue of scalability, hardware issues, and practical aspects of near-term hybrid implementations and give a critical view of the changing role of quantum methods in computational intelligence systems.
Graph Neural Networks (GNNs) are now one of the key tools to model relational and non-Euclidean data in multiagent systems, infrastructure networks and even molecular modeling applications. Nevertheless, in very dense or noisy graph topologies, classical message-passing architectures may experience scalability and representational degeneration, especially due to over-smoothing and insufficient higher-order dependency information. The recent developments in quantum machine learning indicate that hybrid quantum-classical models can also provide an alternative feature representation by projecting relational data to parameterized quantum circuits. This article presents a Quantum-Enhanced Graph Neural Network (QGNN) architecture that extends variational quantum circuits with graph learning pipelines, based on classical learning. Parameters are represented as parameterized qubits, and relational dependencies are represented as structured entanglement mappings. We benchmark the regimes where quantum-enhanced relational encoding proves to be more robust and stable through the swarm coordination, molecular property prediction, and financial transaction network. We also elaborate on the issue of scalability, hardware issues, and practical aspects of near-term hybrid implementations and give a critical view of the changing role of quantum methods in computational intelligence systems.
Abstract Quantum computing has emerged as a powerful tool for modeling molecular systems with high accuracy, accelerating the search for novel therapeutic targets. In this study, we present a two-stage hybrid workflow that combines a Quantum Graph Neural Network with a Variational Quantum Eigensolver to identify potent serine neutralizers in the QM9 dataset. In the first stage, an advanced quantum graph neural network architecture incorporating attention layers, self-distillation, and an adaptive learning-rate schedule is trained to predict ionization potentials and binding free energies. Across five independent random-seed trials, our adaptive-thresholded QGNN–VQE pipeline achieves an average R2 R 2 of 0.990±0.008 0.990 ± 0.008 and a mean absolute error of 0.034±0.001 0.034 ± 0.001 eV ( ≈0.79±0.03 ≈ 0.79 ± 0.03 kcal/mol) on the QM9 validation set, demonstrating robust, chemical-accuracy-level predictions. Building on these high-precision predictions, the second stage employs a QAOA-inspired hybrid ranking scheme that merges quantum graph neural network outputs, feature-space similarity (via and cosine similarity), and variational quantum eigensolver-derived energy stability. This α α -weighted ( α=0.95 α = 0.95 ) scoring framework is applied to over 133,000 molecules, efficiently parsed in parallel. The final ranked list is validated through an improved bijection test, featuring an adaptive similarity threshold to ensure both structural and functional robustness. The top-scoring candidate identified by our pipeline is 5,6,7-tetrahydro-4 H-pyrazolo[4,3-c]pyridin-4-one, highlighting the efficacy of quantum-enhanced modeling in pinpointing complex pharmacological targets. These findings underscore the transformative potential of hybrid quantum-classical workflows in drug discovery, offering a flexible blueprint for advanced screening of other critical biomolecular interactions in the rapidly expanding field of quantum biology. GraphicAbstract VQE for Serine Neutralization
Predicting drug-target binding affinity with limited training data remains a central challenge in computational drug discovery. We introduce a hybrid quantum-classical framework combining molecular descriptors with variational quantum circuits for interpretable binding affinity prediction. Seven physicochemical descriptors (MW, logP, TPSA, HBD/HBA, rotatable bonds, aromatic rings) were encoded into 6-qubit variational circuits using parameterized rotations and controlled-Z entanglement. Quantum kernels were extracted and used for regression on 1,200 BindingDB molecules across kinase, GPCR, and protease targets, with external validation on 300 ChEMBL compounds. Performance was compared against SVR, random forest, gradient boosting, and neural network baselines using 100-fold bootstrap validation. Variational quantum regression achieved MSE = 0.056 ± 0.009, outperforming SVR by 32% (0.082 ± 0.013), RF by 28%, and GBM by 24%. Quantum advantage was most significant in low-data regimes (n < 500), where VQR maintained R2 > 0.85 versus R2 < 0.72 for classical methods. External validation confirmed generalization (R2 = 0.83). Our Explainable Quantum Pharmacology framework revealed TPSA and logP as dominant predictive features through gradientbased sensitivity analysis, aligning with established medicinal chemistry principles. Quantum kernels provide measurable, chemically interpretable improvements for molecular property prediction in data-limited scenarios. This work demonstrates practical quantum advantage for early-stage drug discovery applications on near-term quantum hardware.
The pharmaceutical industry faces mounting challenges in drug discovery, where exploring a chemical space exceeding 10 60 possible compounds remains computationally prohibitive. Traditional in-silico screening approaches struggle to capture the quantum mechanical interactions that determine molecular behavior. To overcome these limitations, this study introduces a hybrid quantum–classical machine learning framework that uniquely integrates molecular graph theory with quantum-enhanced learning for accelerated drug discovery. Using the QM9 benchmark dataset containing 133,885 molecules of low-to-medium structural complexity, we extract Laplacian eigenvalue spectra as topological descriptors that preserve both connectivity and electronic information. These features are jointly processed by Random Forest (RF), Support Vector Machine (SVM), and a Variational Quantum Classifier (VQC) in a weighted ensemble architecture designed for balanced generalization. The Quantum Graph Neural Network (QGNN) component achieves 97.5% accuracy, while the hybrid ensemble attains 100.0% accuracy, confirming strong predictive reliability. Although quantum training requires roughly 3.2× longer computation, it captures high-dimensional correlations that classical methods overlook. Overall, the proposed framework bridges the gap between theoretical quantum computing and practical pharmaceutical modeling, providing a scalable, physics-inspired pathway toward intelligent molecular screening and next-generation drug discovery systems.